AOHP has been successful in having four members co-author an article entitled Sharps injuries with Lovenox and generic enoxaparin prefilled sayety syringes: A 12-year retrospective cross-sectional analytical study, published in the June issue of Nursing 2023.
One of the recommendations from the article was to establish a Memorandum of Understanding (MOU) with the FDA to explore the opportunity for the FDA to issue a device alert on Lovenox/enoxaparin pre-filled syringes. Another recommendation was to discuss FDA reporting procedures. AOHP feels a partnership with the FDA will help further our cause to help keep our healthcare personnel safer by reducing needle sticks.
A letter has been crafted and submitted to the FDA to make them aware of these malfunctioning device associated with sharps injuries to users with potential for disease transmission. We are urging the FDA to investigate these devices, publish an alert, and require manufacturers to adopt safer pre-filled syringes. AOHP is willing to assist and support the FDA in resolving this challenging issue.
The AOHP Lovenox Working Group:
Lydia Crutchfield, MA, BSN, RN
Terry Grimmond, FASM, BAgrSc, GrDpAdEd
Maryann Gruden, MSN, RN, FNP, COHN-S/CM
Bobbi Jo Hurst, MBA, BSN, RN, COHN-S